Alveron Pharmaceuticals is a Rotterdam based clinical-stage biopharmaceutical company developing OKL-1111. a small molecule injectable anticoagulant and platelet inhibitor reversal agent for intracerebral hemorrhage. Alveron’s vision is to bring to market the first single agent, single dose therapeutic option for patients experiencing brain bleeds that does not require identification of the active agent in order to determine whether the reversal agent is indicated for use. Currently available reversal agents are anticoagulant-specific, and therefore require time and operational complexity to indicate and dose, lengthening the period from index event to bleeding reversal substantially. A broad-spectrum reversal agent, particularly one that can inhibit antiplatelet agents for which no reversal agent yet exists, would potentially provide an important reduction in hemorrhage expansion, mass effect, mortality, and post-stroke morbidity in this high unmet need population.
Go to website: https://www.alveron.com